Blue, I review Aratana’s PR, and your post is a little off. Only $3.1 million of actual revenue was booked in Q2. $1.9 million was licensing and collaboration. Organic sales dropped much worse..
“In the second quarter of 2018, the Company recognized $1.8 million in net product sales of NOCITA, $1.3 million in net product sales of ENTYCE and $1.9 million in licensing and collaboration revenue from Elanco for GALLIPRANT.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.